Immunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Truist Financial

Truist Financial assumed coverage on shares of Immunome (NASDAQ:IMNM) in a research note released on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $36.00 price target on the stock.

A number of other analysts have also issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Immunome in a research report on Monday, September 22nd. They set a “buy” rating and a $26.00 target price on the stock. Evercore ISI began coverage on Immunome in a report on Friday, August 22nd. They set an “outperform” rating and a $18.00 price objective on the stock. Guggenheim reiterated a “buy” rating and issued a $25.00 target price on shares of Immunome in a research note on Monday, August 25th. JPMorgan Chase & Co. decreased their price target on Immunome from $23.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Finally, Craig Hallum assumed coverage on shares of Immunome in a research note on Friday, September 5th. They set a “buy” rating and a $26.00 price objective for the company. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Immunome Stock Down 0.5%

Shares of NASDAQ:IMNM opened at $18.32 on Monday. The company has a market capitalization of $1.68 billion, a P/E ratio of -6.21 and a beta of 2.17. Immunome has a 52-week low of $5.15 and a 52-week high of $19.16. The stock’s fifty day simple moving average is $15.49 and its 200-day simple moving average is $11.60.

Immunome (NASDAQ:IMNM) last announced its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, sell-side analysts anticipate that Immunome will post -2.21 earnings per share for the current year.

Institutional Trading of Immunome

A number of institutional investors have recently modified their holdings of IMNM. Stoneridge Investment Partners LLC lifted its position in Immunome by 5.4% during the third quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock valued at $143,000 after buying an additional 620 shares in the last quarter. ANTIPODES PARTNERS Ltd lifted its holdings in shares of Immunome by 6.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock valued at $128,000 after acquiring an additional 631 shares in the last quarter. Creative Planning boosted its position in Immunome by 4.0% during the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after purchasing an additional 710 shares during the period. Teacher Retirement System of Texas boosted its position in Immunome by 6.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock worth $172,000 after purchasing an additional 1,188 shares during the period. Finally, Main Management ETF Advisors LLC increased its holdings in Immunome by 1.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 76,944 shares of the company’s stock valued at $716,000 after purchasing an additional 1,248 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.